Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Current Oncology (Toronto, Ont.)|October 1, 2010
Research in castration-resistant prostate cancer: what does the future hold?R J Macfarlane, K N Chi
Journal of Clinical Epidemiology|May 17, 2000
The standard of reporting of health-related quality of life in clinical cancer trialsC W Lee, K N Chi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivoH Miyake, K N Chi, M E Gleave
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 11, 2013
The future of systemic therapies for localised prostate cancerB J Eigl, M E Gleave, K N Chi
Current Oncology (Toronto, Ont.)|May 3, 2019
Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysisE S Tsang, C Forbes, K N Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 16, 2013
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamideK L Noonan, S North, R L Bitting, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2009
Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacyC Kollmannsberger, C Moore, K N Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2009
A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancerJ Michels, S L Ellard, L Le, et al.
Current Oncology (Toronto, Ont.)|September 5, 2008
Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials GroupW R Parulekar, M McKenzie, K N Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2010
Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapiesC Kollmannsberger, S Tyldesley, C Moore, et al.
Pageof 4